Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.67 |
| ▸ | AURKA | O14965 | 8/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | LYN | P07948 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 6/20 | 0.54 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25328493 | 0.91 | SYK (0.65) | SYKJAK2LYNFLT3 | |
| SCHEMBL25327391 | 0.87 | SYK (0.64) | SYKAURKAJAK2LYNFLT3 | |
| SCHEMBL25328838 | 0.85 | SYK (0.65) | SYKJAK2LYNFLT3 | |
| SCHEMBL25328375 | 0.85 | SYK (0.58) | SYKJAK2LYNFLT3GSK3B | |
| SCHEMBL25328502 | 0.83 | SYK (0.66) | SYKAURKAJAK2FLT3MAPK8 | |
| SCHEMBL25328744 | 0.82 | SYK (0.67) | SYKJAK2LYNFLT3GSK3B | |
| SCHEMBL25329037 | 0.81 | SYK (0.64) | SYKJAK2LYNFLT3 | |
| SCHEMBL29492286 | 0.81 | SYK (1.00) | SYKJAK2LYNFLT3 | |
| SCHEMBL29021356 | 0.81 | SYK (1.00) | SYKJAK2LYNFLT3 | |
| SCHEMBL29021357 | 0.81 | SYK (1.00) | SYKJAK2LYNFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285621-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-08-29 | — | — | US | disclosed |
| EP-4217354-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2023-08-02 | — | — | EP | disclosed |
| CN-116323595-A | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022063646-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285621-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | SYK, LCK, BTK | SYK 1/4885AURKA 236/4885JAK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.